Novo Nordisk的糖尿病和肥胖药物Ozempic和Wegovy预计今年销售额将超过65bn。 Novo Nordisk's diabetes and obesity drugs, Ozempic and Wegovy, are projected to exceed $65bn in sales this year.

Novo Nordisk的糖尿病和肥胖药物Ozempic和Wegovy今年的销售额预计将超过650亿美元,远远超过该公司过去30年的研究预算。 Novo Nordisk's diabetes and obesity drugs, Ozempic and Wegovy, are projected to exceed $65 billion in sales this year, far surpassing the company's research budget over the last 30 years. 尽管有人批评高价, Wegovy每月花费1 349.02美元, 专家们认为市场竞争将降低成本,而不是政府干预。 Despite criticism over high prices, with Wegovy costing $1,349.02 monthly, experts believe market competition will lower costs, rather than government intervention. Novo的首席执行官将在参议院听证会上解决价格问题, Novo's CEO will address pricing concerns in a Senate hearing amid rising demand for these treatments.